Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion, Boosting Blood Cancer Pipeline
Summary
Eli Lilly has agreed to acquire Ajax Therapeutics, a clinical-stage biotech focused on next-generation JAK2 inhibitors, for a deal valued at up to $2.3 billion. This acquisition includes an upfront payment and milestone-based payments tied to clinical and regulatory achievements. The strategic move aims to strengthen Lilly's position in the blood cancer therapeutic area and accelerate the development of Ajax's lead candidate, AJ1-11095. This is a material M&A event for Eli Lilly and represents new information not previously captured in the recent timeline.
At the time of this announcement, LLY was trading at $916.02 on NYSE in the Life Sciences sector, with a market capitalization of approximately $865.5B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.